AMPK activity is down-regulated in endothelial cells of GHS-R-/- mice

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 9, 2013, Pages 1770-1780

  Zhang, Min ^a   Fang, Wei Yi ^a   Qu, Xin Kai ^a   Yuan, Fang ^a   Wang, Wei Gang ^b   Fei, Jian ^b   Wang, Zhi Gang ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

AMPK; Atherosclerosis; Cell proliferation; ECs; GHS R

Indexed keywords

GHRELIN; GHRELIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

AMPK; ANIMAL; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; DOWN REGULATION; ECS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; GHS-R-/-; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHENOTYPE; SIGNAL TRANSDUCTION; TIME;

AMPK; ATHEROSCLEROSIS; CELL PROLIFERATION; ECS; GHS-R-/-;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GHRELIN; MICE; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, GHRELIN; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84885436163     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Riccioni G and Sblendorio V. Atherosclerosis: from biology to pharmacological treatment. J Geriatr Cardiol 2012; 9: 305-317.
2. Zhang G, Yin X, Qi Y, Pendyala L, Chen J, Hou D and Tang C. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010; 6: 62-70.
3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
4. Kojima M, Hosoda H, Matsuo H and Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12: 118-122.
5. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K and Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261.
6. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB and Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
7. Katugampola SD, Pallikaros Z and Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 2001; 134: 143-149.
8. Kellokoski E, Kummu O, Serpi R, Lehenkari P, Ukkola O, Kesaniemi YA and Horkko S. Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)-mice. Peptides 2009; 30: 2292-2300.
9. Pang J, Xu Q, Xu X, Yin H, Xu R, Guo S, Hao W, Wang L, Chen C and Cao JM. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. Peptides 2010; 31: 630-638.
10. Kishimoto I, Tokudome T, Hosoda H, Miyazato M and Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol 2012; 59: 8-13.
11. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I, Karkos C, Karayannacos PE, Gerasimidis T and Liapis CD. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118: 75-80.
12. Yano Y, Toshinai K, Inokuchi T, Kangawa K, Shimada K, Kario K and Nakazato M. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009; 204: 590-594.
13. Zhang M, Fang W, Yuan F, Qu X, Liu H, Chen H, Yu Y, Zheng Z and Shen Y. Plasma ghrelin levels are closely associated with stenosis severity and morphology of angiographically-detected coronary atherosclerosis in patients with coronary artery disease. Int J Cardiol 2011; 151: 122-123.
14. Zhang M, Fang WY, Yuan F, Qu XK, Liu H, Xu YJ, Chen H, Yu YF, Shen Y and Zheng ZC. Plasma ghrelin levels are closely associated with severity and morphology of angiographically-detected coronary atherosclerosis in Chineses patients with diabetes mellitus. Acta Pharmacol Sin 2012; 33: 452-458.
15. Hardie DG, Ross FA and Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-262.
16. Luo Z, Zang M and Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010; 6: 457-470.
17. Wu Y, Zhang C, Dong Y, Wang S, Song P, Viollet B and Zou MH. Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo. PLoS One 2012; 7: e35508.
18. Barazzoni R, Semolic A, Cattin MR, Zanetti M and Guarnieri G. Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats. Obesity (Silver Spring) 2013; doi: 10.1002/oby.20454. [Epub ahead of print].
19. Li Y, Hai J, Li L, Chen X, Peng H, Cao M and Zhang Q. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 2013; 43: 376-386.
20. Sun Y, Wang P, Zheng H and Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004; 101: 4679-4684.
21. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E and Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-1037.
22. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M and Grossman AB. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009; 16: 1329-1338.
23. van der Lely AJ, Tschop M, Heiman ML and Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457.
24. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB and Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280: 25196-25201.
25. Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M and Santiemma V. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis 2009; 203: 97-104.
26. Zhang M, Yuan F, Liu H, Chen H, Qiu X and Fang W. Inhibition of proliferation and apoptosis of vascular smooth muscle cells by ghrelin. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 769-776.
27. Dandapani M and Hardie DG. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? Biochem Soc Trans 2013; 41: 687-693.
28. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T and Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004; 110: 444-451.
29. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa T and Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005; 97: 837-844.
30. Caliskan Y, Gorgulu N, Yelken B, Yazici H, Oflaz H, Elitok A, Turkmen A, Bozfakioglu S and Sever MS. Plasma ghrelin levels are associated with coronary microvascular and endothelial dysfunction in peritoneal dialysis patients. Ren Fail 2009; 31: 807-813.
31. Kellokoski E, Kunnari A, Jokela M, Makela S, Kesaniemi YA and Horkko S. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009; 58: 1572-1580.
32. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW and Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003; 278: 31629-31639.
33. Suzuki K, Uchida K, Nakanishi N and Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens 2008; 21: 451-457.
34. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC and Zou MH. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 2010; 121: 792-803.
35. Salminen A, Hyttinen JM and Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011; 89: 667-676.